Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

DBCOND0138147Neoplasms

Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) is the indication for 5 drugs in DrugBank. It is covered by 14 curated, structured indications.

Also known as: metastatic Squamous cell carcinoma of head and neck · Metastatic Head and Neck Cancer · Metastatic Head and Neck Squamous Cell Carcinoma · Metastatic Head-and-neck Squamous-cell Carcinoma · Metastatic Squamous Cell Carcinoma of the Head and Neck
Classified under: Neoplasms
Indicated drugs: Cetuximab
Docetaxel
Hyaluronidase (human recombinant)
Nivolumab
Pembrolizumab

Resolves to

Vocabularies

MedDRA10071540UMLSC0744619

What you can answer from here — as of October 23, 2026

5Indicated drugsWith each drug's targets and mechanism

Listed above

14Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

69Clinical trialsPhase, status and sponsor resolved per trial

Which approved drugs for Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account